PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Drugs
982044553	rs699	PMID:19286758	AGT	Genotypes AG + GG are not associated with response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	no	= 0.152	59		Unknown	Efficacy	false	No significant difference in the 99mTc-MAG3 clearance (MAG3cle) values after treatment with captopril was seen between G allele carriers and AA homozygotes. MAG3cle provides an estimation of effective renal plasma flow (ERPF), and therefore of responsiveness to captopril treatment.	captopril
769156826	rs12255372	PMCID:PMC2850440	TCF7L2	Allele T is associated with increased risk of Diabetes Mellitus, Type 2.	yes	= 0.0178	510	847	European		false		
1449645155	rs316019	PMID:29914345	SLC22A2	Genotypes AA + AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.0064			Central/South Asian	Efficacy	false	Alleles complemented to plus chromosomal strand. OR is given for likelihood of being non-responder.	metformin
769156829	rs5215	PMCID:PMC2850440	KCNJ11	Allele C is not associated with increased risk of Diabetes Mellitus, Type 2.	no	= 0.8728	527	882	European		false	This was a test of replication of an association found in another study and whether the same association could be found through BioVU-EMR data. The association is consistent with other studies, but in this study it was not significant.	
981345659	rs1801262	PMCID:PMC3477351	NEUROD1	Genotypes CT + TT are associated with decreased difference in fasting plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	< 0.01	43		East Asian	Efficacy	false	Note: Alleles have been complemented to the + strand.	repaglinide
1447954507	rs1896832	PMCID:PMC4804508		Allele T is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.16	674		East Asian	Efficacy	false		aspirin; clopidogrel
1451412868	rs163184	PMID:32504053	KCNQ1	Allele G is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.033	78	227	African American/Afro-Caribbean	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from ALFA, it is assumed that the G and T alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
1296666702	rs6467136	PMID:24752311	PAX4	Genotypes AA + AG are not associated with response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	no	= 0.0063	91		East Asian	Efficacy	false	No significant differences in any clinical parameters (e.g. body mass index, fasting glucose, 2-hour glucose) or attainment rates of target fasting glucose, 2-hour glucose or glycated hemoglobin were seen after 48 weeks of treatment between the genotypes.	repaglinide
1449164647	rs2943641	PMID:28696414	IRS1	Allele T is not associated with response to Drugs Used In Diabetes in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.54	1211	1391	Unknown	Efficacy	false	Cases were patients requiring insulin therapy added either on or instead of maximal or near-maximal doses of oral antidiabetes drugs (OADs). Controls were patients who were in acceptable glycemic control (HbA1c<=8%) in the absence of insulin therapy. OADs were mostly sulfonylureas and metformin; 2-4% of patients were also on thiazolidinediones and/or gliptins.	Drugs Used In Diabetes
1451412874	rs2237892	PMID:32504053	KCNQ1	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.52	78	227	African American/Afro-Caribbean	Toxicity	false	Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
769156817	rs4506565	PMCID:PMC2850440	TCF7L2	Allele T is associated with increased risk of Diabetes Mellitus, Type 2.	yes	= 0.0093	532	886	European		false		
1449645164	rs12943590	PMID:29914345	SLC47A2	Genotypes AA + AG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.035	98	90	Central/South Asian	Efficacy	false	OR is given for likelihood of being non-responder.	metformin
1447954498	rs1801278	PMCID:PMC4804508	IRS1	Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.59	674		East Asian	Efficacy	false		aspirin; clopidogrel
769156821	rs12243326	PMCID:PMC2850440	TCF7L2	Allele C is associated with increased risk of Diabetes Mellitus, Type 2.	yes	= 0.0169	520	876	European		false		
827641434	rs5219	PMID:11318841	KCNJ11	Genotype TT is associated with increased likelihood of Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.0072	360	307	European		false		
1451412620	rs1799854	PMID:32504053	ABCC8	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.	no	= 0.68	356	1039	European	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from gnomAD, it is assumed that the A and G alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
981239923	rs36056065	PMID:22735389	SLC22A1	Allele GTAAGTTG is associated with gastrointestinal side effects when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele del.	yes	= 0.002	41	193	European	Metabolism/PK,Toxicity	false		metformin
1451412626	rs1799859	PMID:32504053	ABCC8	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.17	356	1039	European	Toxicity	false	Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
769162953	rs4149056	PMCID:PMC3353487	SLCO1B1	Allele C is associated with increased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele T.	not stated	= 0.0427	816	1275	Unknown	Toxicity	false	The association was found with general intolerance to statins in a logistic regression model accounting for age, both the genotypes, statin adherence, study duration, maximum dose, and concomitant prescriptions for other lipid-regulating drugs and CYP3A4 inhibiting drugs. Intolerance (Abnormalities, Drug-Induced) was defined by serum biochemistry and also by discontinuation, switching, or reduction in dose of the prescribed statin drug.	hmg coa reductase inhibitors
769156810	rs4402960	PMCID:PMC2850440	IGF2BP2	Allele T is not associated with increased risk of Diabetes Mellitus, Type 2.	no	= 0.9787	527	877	European		false	This was a test of replication of an association found in another study and whether the same association could be found through BioVU-EMR data. The association is consistent with other studies, but in this study it was not significant.	
1449164659	rs7578326	PMID:28696414	IRS1	Allele G is not associated with response to Drugs Used In Diabetes in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.66	1180	1394	Unknown	Efficacy	false	Cases were patients requiring insulin therapy added either on or instead of maximal or near-maximal doses of oral antidiabetes drugs (OADs). Controls were patients who were in acceptable glycemic control (HbA1c<=8%) in the absence of insulin therapy. OADs were mostly sulfonylureas and metformin; 2-4% of patients were also on thiazolidinediones and/or gliptins.	Drugs Used In Diabetes
1452234140	rs143276236	PMID:37639712	ARFGEF3	Genotype AC is associated with decreased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 6.39e-9	292		African American/Afro-Caribbean	Efficacy	false	"as measured by change in A1C. ""Among individuals with>425 mg/day average daily exposure to metformin, individuals with the ARFGEF3 rs143276236 CC genotype had an average absolute HbA1c reduction of 0.59% whereas individuals with the AC genotype had an average absolute HbA1c reduction of 0.28%; these differences were statistically significant"""	metformin
769162956	rs2306283	PMCID:PMC3353487	SLCO1B1	Allele G is associated with decreased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele A.	not stated	= 0.0257	816	1275	Unknown	Toxicity	false	Carrier of G allele showed general tolerance to statins in a logistic regression model accounting for age, both the genotypes, statin adherence, study duration, maximum dose, and concomitant prescriptions for other lipid-regulating drugs and CYP3A4 inhibiting drugs. Intolerance (Abnormalities, Drug-Induced) was defined by serum biochemistry and also by discontinuation, switching, or reduction in dose of the prescribed statin drug.	hmg coa reductase inhibitors
769156814	rs10811661	PMCID:PMC2850440		Allele C is not associated with increased risk of Diabetes Mellitus, Type 2.	no	= 0.3269	534	887	European		false	This was a test of replication of an association found in another study and whether the same association could be found through BioVU-EMR data. The association is consistent with other studies, but in this study it was not significant.	
981239914	rs628031	PMID:22735389	SLC22A1	Allele A is associated with gastrointestinal toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 0.009	41	193	European	Metabolism/PK,Toxicity	false		metformin
1447954516	rs956115	PMCID:PMC4804508		Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.15	674		East Asian	Efficacy	false		aspirin; clopidogrel
981502876	rs2237892	PMID:22414228	KCNQ1	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.025	40		East Asian	Efficacy	false	Patients with the CT and TT genotypes had a greater decrease in postprandial plasma glucose (PPG) levels between baseline and after 8 weeks of treatment, compared to those with the CC genotype.	repaglinide
1296666710	rs10229583	PMID:24752311	PAX4	Genotypes AA + AG are not associated with response to repaglinide or rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	no	= 0.0063	91	93	East Asian	Efficacy	false	No significant differences in any clinical parameters (e.g. body mass index, fasting glucose, 2-hour glucose) or attainment rates of target fasting glucose, 2-hour glucose or glycated hemoglobin were seen after 48 weeks of treatment between the genotypes. Study Size and Frequency below: repaglinide cohort/rosiglitazone cohort.	repaglinide; rosiglitazone
1450375507	rs3765467	PMID:30883264	GLP1R	Allele A is associated with decreased response to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele G.	no	= 0.07	289		Unknown	Efficacy	false	"as measured by weight loss and HbA1c reduction, but this association was only marginal. Alleles complemented, paper states ""mutant T allele of rs3765467, which causes an amino acid change from Arg to Gln, was marginally associated with HbA1c reduction""."	exenatide
1448105842	rs2289669	PMID:22882994	SLC47A1	Genotype AA is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.	yes	= 0.018	148		European	Efficacy	false	This is measured as increased reduction of HbA1c (better response) after 6-month metformin therapy when treated with metformin. Reduction of HbA1c in AA homozygotes was doubled in comparison with G-allele carriers (GG +AG) and the difference remained statistically significant after adjustment for covariates (GG + GA: 0.55±0.18% vs. AA: 1.10±0.08%; p = 0.008, padj = 0.018).	metformin
981502885	rs2237895	PMID:22414228	KCNQ1	Genotypes AC + CC are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	yes	= 0.001	40		East Asian	Efficacy	false	Patients with the AC and CC genotypes had a greater increase in postprandial serum insulin levels between baseline and after 8 weeks of treatment, compared to those with the AA genotype.	repaglinide
1451412903	rs1057868	PMID:32504053	POR	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.36	78	227	African American/Afro-Caribbean	Toxicity	false	This is also referred to in the paper as the POR*28 allele. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
1183574189	rs11212617	PMCID:PMC3369131	C11orf65	Allele C is associated with increased treatment success when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	yes	= 0.0000078	4443		Unknown	Efficacy	false		metformin
655388472	rs1799722	PMID:11699055	BDKRB2	Allele T is not associated with increased risk of ACEI-related cough when treated with perindopril in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.314	189		East Asian	Toxicity	false		perindopril
1451412650	rs5219	PMID:32504053	ABCC8; KCNJ11	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.51	356	1039	European	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from gnomAD, it is assumed that the C and T alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
1451934880	rs622342	PMID:34545025	SLC22A1	Genotype AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + CC.	yes	< 0.05	71		East Asian	Efficacy	false	Compared with the AA or CC genotype, patients with AC genotype of rs622342 achieved greater reduction in Δ60FPG and Δ(60–30)FPG (P = 0.00820, 0.00089, respectively). Association between genotypes and the efficacy of metformin with regression analysis, which adjusted for several variables, including age, BMI, sex, the dose of metformin, education, tea drink, smoking, and sweet. Patients were eligible for the study if they had newly diagnosed T2DM and could not achieve an appropriate FPG level.	metformin
1447945831	rs2237897	PMID:26866747	KCNQ1	Genotypes CT + TT are associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.006	443		East Asian	Efficacy	false	Fasting plasma glucose (FPG) had a greater reduction in CT and TT subjects vs CC and a higher rate of treatment success was found in T carriers.	gliclazide
1296666726	rs6467136	PMID:24752311	PAX4	Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.0033	41		East Asian	Efficacy	false	Subset of patients with defective beta-cell function. Those with the AA or AG genotype had a greater decrease in body mass index (BMI) after 48 weeks of treatment, as compared to GG homozygotes. Those with the AA and AG genotypes also showed a greater improvement of HOMA-IR as compared to GG homozygotes.  Lastly, those with the AA and AG genotypes were significantly more likely to attain the standard fasting plasma glucose and 2-hour glucose levels as compared to GG homozygotes at all assessment points between 0 and 48 weeks of treatment. Note that these effects were not seen in the subgroup with normal beta-cell function.	rosiglitazone
1450810953	rs1052700	PMID:16732015	PLIN1	Allele T is not associated with Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele A.	no		160		Unknown	Toxicity	false	Reported as 14995A>T in the paper.	rosiglitazone
1451581367	rs2237892	PMID:34665019	KCNQ1	Allele C is not associated with increased likelihood of Hypoglycemia when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.749	120	281	"Multiple groups, From Table 2: Race Malay Chinese Indian Iban Bidayuh Melanau Bajau Kadazan Dusun Suluk"	Toxicity	false	"""The genetic association analysis revealed that the genotypes and alleles for ABCC8 rs757110, KCNJ11 rs5219, CDKAL1 rs7756992 and KCNQ1 rs2237892 polymorphisms were all not significantly associated with sulfonylurea-induced hypoglycemia""""Sulfonylurea-induced hypoglycemia was defined as having at least one symptomatic hypoglycemia episode with or without a blood glucose level <3.9 mmol/l during the 12-month follow-up."""	sulfonamides, urea derivatives
1450935112	CYP2C8*1; CYP2C8*3	PMID:23426382	CYP2C8	CYP2C8 *1/*3 + *3/*3 are associated with decreased concentrations of rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to CYP2C8 *1/*1.	no	= 0.06	187		Unknown	Metabolism/PK	false	"The authors found borderline, statistically nonsignificantly lower trough steady-state concentrations in carriers of CYP2C8*3.""Excluding the CYP2C8*3 homozygotes (n=1) and comparing homozygotes for the wild type with heterozygotes, a statistically significant effect of the SNP was found (23.1 vs. 16.5 ng/ml, P=0.03)"""	rosiglitazone
1452554144	HLA-DQB1*03:01	PMID:39091267	HLA-DQB1	HLA-DQB1 *03:01 is associated with increased likelihood of Pemphigoid, Bullous when treated with Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus, Type 2.	yes	< 0.0002	86	30	European	Toxicity	false	"""Of note, 86 BP patients with concomitant T2D treated with gliptins (GABP) were strongly associated with DQB1*03:01 allele when compared with both T2D and ND controls (69.2% vs. 28.3% and 32.0%; p < 0.00001 and pc = 0.0002 in both cases) (Table 1). Noteworthy, almost all GABP patients (95.3%) possessed at least one DQB1*03:01 allele, while only 50.0% and 54.5% did the same in the control groups (T2D and ND, respectively) (p < 0.00001 and pc = 0.0002 in both cases) (Table 1)."" GABP, gliptin-associated bullous pemphigoid"	Dipeptidyl peptidase 4 (DPP-4) inhibitors
1451581360	rs7756992	PMID:34665019	CDKAL1	Allele A is not associated with increased likelihood of Hypoglycemia when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele G.	no	= 0.871	120	281	"Multiple groups, From Table 2: Race Malay Chinese Indian Iban Bidayuh Melanau Bajau Kadazan Dusun Suluk"	Toxicity	false	"""The genetic association analysis revealed that the genotypes and alleles for ABCC8 rs757110, KCNJ11 rs5219, CDKAL1 rs7756992 and KCNQ1 rs2237892 polymorphisms were all not significantly associated with sulfonylurea-induced hypoglycemia""""Sulfonylurea-induced hypoglycemia was defined as having at least one symptomatic hypoglycemia episode with or without a blood glucose level <3.9 mmol/l during the 12-month follow-up."""	sulfonamides, urea derivatives
1450375492	rs10305420	PMID:30883264	GLP1R	Allele T is associated with decreased response to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele C.	yes	= 0.002	289		Unknown	Efficacy	false	as measured by weight loss and HbA1c reduction.	exenatide
769156833	rs5219	PMCID:PMC2850440	KCNJ11	Allele T is not associated with increased risk of Diabetes Mellitus, Type 2.	no	= 0.958	533	888	European		false	This was a test of replication of an association found in another study and whether the same association could be found through BioVU-EMR data. The association is consistent with other studies, but in this study it was not significant.	
981785277	rs10192566	PMID:23426382	LPIN1	Allele C is not associated with trough rosiglitazone steady-state concentration when treated with rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele G.	no	= 0.28	187		Unknown	Metabolism/PK	false		rosiglitazone
1449164633	rs1801278	PMID:28696414	IRS1	Genotypes CT + TT is associated with decreased response to Drugs Used In Diabetes in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.001			Unknown	Efficacy	false	Cases were patients requiring insulin therapy added either on or instead of maximal or near-maximal doses of oral antidiabetes drugs (OADs). Controls were patients who were in acceptable glycemic control (HbA1c<=8%) in the absence of insulin therapy. OADs were mostly sulfonylureas and metformin; 2-4% of patients were also on thiazolidinediones and/or gliptins. Individuals carrying the minor T allele tended to be more frequent among cases as compared to controls. When this data was meta-analyzed with a previous independent study (Sesti et al. (2004) PMID: 15161794), significant results were also obtained. Please note that alleles have been complemented to the plus chromosomal strand.	Drugs Used In Diabetes
1451412920	rs2237895	PMID:32504053	KCNQ1	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.11	78	227	African American/Afro-Caribbean	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from ALFA, it is assumed that the A and C alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
769156836	rs8050136	PMCID:PMC2850440	FTO	Allele A is not associated with increased risk of Diabetes Mellitus, Type 2.	no	= 0.4731	533	886	European		false	This was a test of replication of an association found in another study and whether the same association could be found through BioVU-EMR data. The association is consistent with other studies, but in this study it was not significant.	
1448601704	rs659366	PMID:23621569	UCP2	Allele T is not associated with risk of when treated with clopidogrel in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.57	405		East Asian	Toxicity	false		clopidogrel
1450810937	rs2289487	PMID:16732015	PLIN1	Allele C is not associated with Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele T.	no		160		Unknown	Toxicity	false	Reported as 6209G>A in the paper. Please note that alleles have been complemented to the positive strand.	rosiglitazone
981785285	rs1801282	PMID:23426382	PPARG	Allele C is not associated with differences in the trough rosiglitazone steadystate concentrations or in the absolute decrease in HbA1c, nor did it affect the risk of developing oedema when treated with rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele G.	no		187		Unknown	Efficacy	false		rosiglitazone
1447954445	rs13431554	PMCID:PMC4804508	IRS1	Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to genotype AA.	yes	< 0.001	674		East Asian	Efficacy	false	The  G  allele  frequency  of  rs13431554  was  significantly  higher  in  the  high platelet reactivity (HPR) group  compared  with  the  non-HPR  group  (27.7  vs  18.6  %  in coronary artery disease (CAD) patients with type 2 diabetes mellitus (T2DM).	aspirin; clopidogrel
1184466652	rs149711321	PMCID:PMC4171106	PPARA	Allele T is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	yes	= 5.10E-05	440		Multiple groups	Efficacy	false		metformin
1448603665	rs9924771	PMID:28134748	SLC5A2	Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no		979		Unknown	Efficacy	false	No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed.	empagliflozin
1450810943	rs2304795	PMID:16732015	PLIN1	Allele G is not associated with Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele A.	no		160		Unknown	Toxicity	false	Reported as 13041A>G in the paper.	rosiglitazone
827816208	rs757110	PMID:22176616	ABCC8	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.27	111	100	Unknown	Toxicity	false	The risk is for severe sulfonylurea-induced Hypoglycemia.	glimepiride; glyburide; sulfonamides, urea derivatives
1444712539	rs2289669	PMID:26004431	SLC47A1	Genotype AA is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.	yes	< 0.05	220		East Asian	Efficacy	false	Subjects with variant genotype (AA) had significantly greater decline of HbA1c level than other two groups (-2.32% [-25.4mmol/mol] in AA vs. -1.16% [-12.7mmol/mol] in GA, -1.07% [-11.7mmol/mol] in GG, P<0.05) after one-year follow-up.	metformin
1451412680	rs1801278	PMID:32504053	IRS1	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.12	78	227	African American/Afro-Caribbean	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from gnomAD, it is assumed that the C and T alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
1448603676	rs11646054	PMID:28134748	SLC5A2	Allele C is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no		979		Unknown	Efficacy	false	No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed.	empagliflozin
1184466644	rs784888	PMCID:PMC4171106	SP1	Allele G is associated with decreased severity of Hyperglycemia when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	yes	= 0.01705	440		Multiple groups	Efficacy	false		metformin
1451412688	rs2943641	PMID:32504053		Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.045	78	227	African American/Afro-Caribbean	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from gnomAD, it is assumed that the C and T alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
1451934940	rs11212617	PMID:34545025	ATM	Genotype AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + CC.	yes	< 0.05	71		East Asian	Efficacy	false	Patients with the AC genotype of rs11212617 achieved significantly lower FPG than that of patients with AA or CC homozygote of rs11212617, including Δ30FPG and respectively). Association between genotypes and the efficacy of metformin with regression analysis, which adjusted for several variables, including age, BMI, sex, the dose of metformin, education, tea drink, smoking, and sweet. Patients were eligible for the study if they had newly diagnosed T2DM and could not achieve an appropriate FPG level.	metformin
981785298	rs8192678	PMID:23426382	PPARGC1A	Allele C is not associated with differences in the trough rosiglitazone steadystate concentrations or in the absolute decrease in HbA1c, nor did it affect the risk of developing oedema when treated with rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele T.	no		187		Unknown	Efficacy	false		rosiglitazone
1451412180	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:32504053	CYP2C9	CYP2C9 *2 + *3 are not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to CYP2C9 *1.	no	= 0.30	356	1039	European	Toxicity	false	Bonferroni-adjusted threshold for statistical significance was set at p<0.0033	glimepiride; glipizide; glyburide
1450810926	rs894160	PMID:16732015	PLIN1	Genotypes CT + TT are associated with decreased Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.005	160		Unknown	Toxicity	false	Reported as 11482G>A in the paper. There was a significant additive effect of the T allele on weight gain associated with rosiglitazone treatment. Please note that alleles have been complemented to the positive strand.	rosiglitazone
981785309	rs2970847	PMID:23426382	PPARGC1A	Allele C is not associated with differences in the trough rosiglitazone steadystate concentrations or in the absolute decrease in HbA1c, nor did it affect the risk of developing oedema when treated with rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele T.	no		187		Unknown	Efficacy	false		rosiglitazone
1447954455	rs2251692	PMCID:PMC4804508		Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.58	674		East Asian	Efficacy	false		aspirin; clopidogrel
1448617223	rs1131882	PMCID:PMC5352797	TBXA2R	Allele A is associated with increased risk of Death when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 0.029	237		European	Efficacy,Toxicity	false	"This variant is associated with primary and secondary endpoints of diabetic patients treated with aspirin. The primary endpoint was defined as death from any cause. The secondary endpoint included primary endpoint and thromboischemic events, such as ischemic stroke, myocardial infarction, transient ischemic attack, acute ophthalmic artery thrombosis and acute lower limb thrombosis."	aspirin
1448603703	rs3813008	PMID:28134748	SLC5A2	Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no		979		Unknown	Efficacy	false	No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed.	empagliflozin
981501160	rs10494366	PMCID:PMC2860533	NOS1AP	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 0.013	100		East Asian	Dosage,Efficacy	false	TT subjects had more serious insulin resistance at baseline, but had increased response (HOMA-IR) to repaglinide than TG  and GG subjects.  TG subjects had a lesser response, while GG subjects had an increase in HOMA-IR after treatments.	repaglinide
1447954471	rs10205923	PMCID:PMC4804508	IRS1	Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.09	674		East Asian	Efficacy	false		aspirin; clopidogrel
769268144	rs757110	PMID:21142918	ABCC8; KCNJ11	Allele A is not associated with increased risk of Hypoglycemia when treated with glibenclamide and glimepiride in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.09	32	125	Unknown	Toxicity	false		glimepiride; glyburide
827695929	rs1057910	PMID:21121772	CYP2C9	Genotype AC is associated with decreased dose of glimepiride in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	no	= 0.07	59		Unknown	Dosage,Metabolism/PK	false	The study noted a trend for a lower stable dose in CYP2C9*3 carriers (*1/*3 (AC) or *2/*3) compared to CYP2C9*1 homozygotes (AA), though this did not reach statistical significance.	glimepiride
1452405500	rs7903146	PMID:38453649	TCF7L2	Allele T is not associated with increased clinical benefit to semaglutide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.42	191		European	Efficacy	false	Carriers of at least one rs7903146 ‘T’ allele and rs7202877 ‘G’ allele presented similar glucose control and weight loss response to GLP-1 RAs with the respective homozygous wild-type genotypes [odds ratio (OR): 1.08, 95% confidence interval (CI): 0.5, 2.31, p = 0.85 and OR: 1.35, 95% CI: 0.66, 2.76, p = 0.42; OR: 1.4, 95% CI: 0.56, 3.47, p = 0.47 and OR: 1.28, 95% CI: 0.55, 2.98, p = 0.57, respectively].	semaglutide
827814949	rs7903146	PMID:21114608	TCF7L2	Genotype CC is associated with increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.	yes	= 0.003	87		Unknown	Efficacy	false		sulfonamides, urea derivatives
1184466667	rs10747673	PMCID:PMC4171106		Allele G is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	yes	= 0.01	440		Multiple groups	Efficacy	false		metformin
1448603685	rs3116149	PMID:28134748	SLC5A2	Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no		979		Unknown	Efficacy	false	No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed.	empagliflozin
827785764	rs296766	PMID:21934636	AQP2	Allele T is associated with increased risk of Edema when treated with thiazolidinediones in people with Diabetes Mellitus, Type 2 as compared to allele C.	yes	= 0.0059	268		East Asian	Toxicity	false		thiazolidinediones
1452188920	rs3889348	PMID:37458617	SLC29A4	Allele G is associated with increased severity of gastrointestinal toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	yes	= 0.012	103	206	East Asian	Toxicity	false	"effect is described for metformin intolerance and severity. "" Metformin intolerance was independently associated with the G allele at rs3889348"" ""The single-nucleotide polymorphism rs3889348 is associated with metformin-induced adverse gastrointestinal effects. Each additional copy of the G allele increases the score by 5.23 (95% CI: 1.82-8.64; p = 0.003)."""	metformin
1296666686	rs6467136	PMID:24752311	PAX4	Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.0063	93		East Asian	Efficacy	false	Those with the AA or AG genotype had a greater decrease in 2-hour glucose levels after 48 weeks of treatment and a greater decrease in body mass index (BMI) after 48 weeks of treatment, as compared to GG homozygotes. Those with the AA and AG genotypes were also significantly more likely to attain the standard 2-hour glucose level as compared to GG homozygotes at all assessment points between 0 and 48 weeks of treatment.	rosiglitazone
1447954489	rs2288586	PMCID:PMC4804508	IRS1	Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.11	674		East Asian	Efficacy	false		aspirin; clopidogrel
1448603694	rs3116150	PMID:28134748	SLC5A2	Allele A is not associated with response to empagliflozin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no		979		Unknown	Efficacy	false	No relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed.	empagliflozin
1184466659	rs2683511	PMCID:PMC4171106	SP1	Allele C is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.	yes	= 0.01	440		Multiple groups	Efficacy	false		metformin
1183491316	rs1799752	PMID:20830509	ACE	Genotype del/del is associated with increased response to losartan in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	yes		140		Near Eastern	Efficacy	false	This SNP was presented as ACE I/D. Patients with Type II Diabetes Mellitus that also had macroalbuminuria with the DD genotype had a better response to losartan as compared to patients carrying the I allele, or with normoalbuminuria.	losartan
1447954480	rs1078533	PMCID:PMC4804508	IRS1	Allele C is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.48	674		East Asian	Efficacy	false		aspirin; clopidogrel
1444712547	rs2289669	PMID:26004431	SLC47A1	Genotype AA is associated with decreased clearance of metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.	yes	< 0.01	220		East Asian	Metabolism/PK	false	Patients carrying homozygous A had higher area under the plasma concentration versus time curve (AUC12h), but lower renal clearance (CLR) and renal clearance by secretion (CLSR) of metformin than other patients (all P<0.01).	metformin
1450935044	CYP2C8*3	PMID:23426382	CYP2C8	CYP2C8 *3 is associated with decreased mean absolute difference in HbA1c when treated with rosiglitazone in people with Diabetes Mellitus, Type 2.	yes	= 0.0121	187		Unknown	Efficacy	false	Higher HbA1c values at 6 (2.9%, P=0.0121) and 24 (1.55%, P=0.0491) month of treatment compared to non-carrier. Rs10509681 was used as marker SNP for CYP2C8*3. The authors states that rs10509681 was in complete linkage disequilibrium with rs11572080.	rosiglitazone
827864536	rs11212617	PMCID:PMC3030919	C11orf65	Allele C is associated with treatment success, achieving an HbA1c below 7% when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	not stated	= 1.9E-7	1024		European	Efficacy	false	For the second replication set in the UK cohort (Prospective Diabetes (UKPDS) cohort), study genotyped the proxy SNP rs609261 (r2 = 0.997 with rs11212617 in 5,197 WTCCC2 controls) for technical reasons.	metformin
1450935033	CYP2C8*3	PMID:23426382	CYP2C8	CYP2C8 *3 is associated with decreased risk of Edema when treated with rosiglitazone in people with Diabetes Mellitus, Type 2.	no	= 0.054	187		Unknown	Toxicity	false	Association showed a borderline significance. lower OR for developing oedema during rosiglitazone treatment	rosiglitazone
1448631772	rs2252281	PMCID:PMC5425333	SLC47A1	Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.68	2651		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
1449563874	rs2289669	PMID:29790415	SLC47A1	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 0.006	331		European	Efficacy	false	as measured by increase in Z score (which includes HbA1c and daily dose of insulin) at the end of the study (approx 4 years).	metformin
1448631760	rs316019	PMCID:PMC5425333	SLC22A2	Allele A is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.33	5224		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
1448099032	rs6923761	PMID:27160388	GLP1R	Genotype AA is associated with decreased response to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.011	140		European	Efficacy	false	The main study outcome was reduction of HbA1c after 6-months of uninterrupted treatment with glistens. The genetic association was significant with an additive genetic model.	sitagliptin; vildagliptin
1183943963	G6PD A- 202A_376G	PMID:21147013	G6PD	G6PD A-202A_376G/A-202A_376G (assigned as deficiency phenotype) is associated with Hemolysis when treated with glibenclamide in women with Diabetes Mellitus, Type 2.	not stated		1		Sub-Saharan African	Toxicity	false	Homozygous for the A- variant (the two genetic variants were described). Hemolysis occurred after admission for a hyperglycemic state, which may result in further G6PD deficiency.	glyburide
1183491329	rs1799752	PMID:20830509	ACE	Genotype del/del is associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	yes		140		Near Eastern	Efficacy	false	This SNP was presented as ACE I/D. Patients with Type II Diabetes Mellitus that were normoalbuminuric with the DD genotype had a better response to captopril as compared to patients carrying the I allele, or with macroalbuminuria.	captopril
655385756	rs5219	PMID:20054294	KCNJ11	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.018	40		East Asian	Efficacy	false		repaglinide
1449563883	rs11212617	PMID:29790415	ATM	Allele C is associated with decreased concentrations of metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.0128	155		European	Metabolism/PK	false	"Authors state is ""close to significance with application of the Bonferroni method"""	metformin
1448631766	rs2289669	PMCID:PMC5425333	SLC47A1	Allele A is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no	= 0.83	5205		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
1451413004	rs10494366	PMID:32504053	NOS1AP	Allele T is associated with increased risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 0.003	78	227	African American/Afro-Caribbean	Toxicity	false	This association was significant in African American patients, but not in European Americans. The authors present the data as exploratory and caution that the analysis is not well-powered. The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from gnomAD, it is assumed that the G and T alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
981481488	rs328	PMID:17394430	LPL	Genotypes CG + GG are associated with decreased response rate after 10 weeks of pioglitazone treatment when treated with pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.0403	113		East Asian	Efficacy	false	"Pioglitazone treatment may also have significantly beneficial effects on serum lipid profile and blood pressure in S447S (CC) genotype carriers than the S447X (GG+CG) carriers."	pioglitazone
1448631754	rs622342	PMCID:PMC5425333	SLC22A1	Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.26	5434		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
1450376171	rs5219	PMID:22264780	KCNJ11	Genotypes CT + TT is associated with increased risk of Diabetes Mellitus, Type 2 when treated with tacrolimus in people with heart transplantation or Kidney Transplantation as compared to genotype CC.	yes	= 0.03	115	205	European	Toxicity	false	New-onset diabetes after transplantation (NODAT). Please note that alleles have been complemented to the plus chromosomal strand.	tacrolimus
827807950	rs16889462	PMID:20809084	SLC30A8	Genotype AG is associated with increased efficacy when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	< 0.05	48		East Asian	Efficacy	false		repaglinide
981481498	rs1801282	PMID:12610044	PPARG	Allele G is not associated with efficacy of pioglitazone when treated with pioglitazone in people with Diabetes Mellitus, Type 2 as compared to allele C.	no		131		Unknown	Efficacy	false		pioglitazone
769218882	rs1057910	PMID:21121772	CYP2C9	Allele C is not associated with increased stable dose of glibenclamide, gliclazide, glimepiride and tolbutamide in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.48	152		Unknown	Dosage,Metabolism/PK	false	Please note; there was a mixed population of individuals on each sulfonylurea drug. No significant differences were found between carries of CYP2C9 allele *1/*1 vs *1/*3 or *2/*3 and *1/*2 or *2/ *2 with time to stable dose. rs1057910 refers to CYP2C9*3. [stat_test: kruskal-wallis]	gliclazide; glimepiride; glyburide; tolbutamide
1452405514	rs7202877	PMID:38453649	CTRB1	Allele G is not associated with increased clinical benefit to semaglutide in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.56	191		European	Efficacy	false	Carriers of at least one rs7903146 ‘T’ allele and rs7202877 ‘G’ allele presented similar glucose control and weight loss response to GLP-1 RAs with the respective homozygous wild-type genotypes [odds ratio (OR): 1.08, 95% confidence interval (CI): 0.5, 2.31, p = 0.85 and OR: 1.35, 95% CI: 0.66, 2.76, p = 0.42; OR: 1.4, 95% CI: 0.56, 3.47, p = 0.47 and OR: 1.28, 95% CI: 0.55, 2.98, p = 0.57, respectively].	semaglutide
1448631748	rs72552763	PMCID:PMC5425333	SLC22A1	Allele del is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele GAT.	no	= 0.85	4423		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
1450932964	rs4871827	PMID:31453770	DEPTOR	Genotype AG is associated with decreased likelihood of Diabetic Retinopathy or Kidney Failure, Chronic in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.021	33		European	Other	false	"Authors state patients ""were receiving treatment according to the established clinical guidelines"" in methods and in introduction state ""T2D treatment with nonpharmacological and pharmacological measures"" but no medications or treatments are detailed. These phenotypes were grouped as microvascular complications. ""Interestingly, none of the carriers of polymorphic rs4871827 AA genotype suffered from any macro or microvascular complications"""	
1450932954	rs4871827	PMID:31453770	DEPTOR	Genotype AG is associated with decreased likelihood of Brain Ischemia, Myocardial Infarction or Peripheral Vascular Diseases in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.006	45		European	Other	false	"Authors state patients ""were receiving treatment according to the established clinical guidelines"" in methods and in introduction state ""T2D treatment with nonpharmacological and pharmacological measures"" but no medications or treatments are detailed. These phenotypes were grouped as macrovascular complications. ""Interestingly, none of the carriers of polymorphic rs4871827 AA genotype suffered from any macro or microvascular complications"""	
1451581220	rs757110	PMID:34665019	ABCC8	Allele A is not associated with increased likelihood of Hypoglycemia when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.784	120	281	"Multiple groups, From Table 2: Race Malay Chinese Indian Iban Bidayuh Melanau Bajau Kadazan Dusun Suluk"	Toxicity	false	"""The genetic association analysis revealed that the genotypes and alleles for ABCC8 rs757110, KCNJ11 rs5219, CDKAL1 rs7756992 and KCNQ1 rs2237892 polymorphisms were all not significantly associated with sulfonylurea-induced hypoglycemia""""Sulfonylurea-induced hypoglycemia was defined as having at least one symptomatic hypoglycemia episode with or without a blood glucose level <3.9 mmol/l during the 12-month follow-up."""	sulfonamides, urea derivatives
1452498480	rs72554664	PMCID:PMC11150262	G6PD	Allele T is associated with increased likelihood of Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	< 0.001	4235	81099	Unknown	Other	false	"""The TC + TT genotype was identified as a risk factor for T2DM compared to the CC genotype (OR = 1.95, 95% CI: 1.39–2.75)."" ""male carriers of the T allele had higher odds of diabetes (OR = 3.44; 95% CI: 1.82–6.51) compared to C carriers. Disease risk was also higher among females with the TC + TT genotype compared to their CC genotype counterparts (OR = 1.66; 95% CI: 1.10–2.50). "" ""The TT genotype was exceedingly rare, with its presence being nearly negligible in females and entirely absent in diabetic females.""(n=6)"	
1450932947	rs4871827	PMID:31453770	DEPTOR	Genotypes AA + AG is associated with increased HDL cholesterol in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.008	178		European	Other	false	"Authors state patients ""were receiving treatment according to the established clinical guidelines"" in methods and in introduction state ""T2D treatment with nonpharmacological and pharmacological measures"" but no medications or treatments are detailed."	
769169522	rs889299	PMID:18004211	SCNN1B	Allele A is associated with oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 5.0E-4	33	39	European	Toxicity	false	Please note: This polymorphism was found to have a significant association with oedema - the risk allele and minor allele was not clearly defined in this study, therefore the minor/ variant allele in Caucasian populations was used in this curation. [stat_test: chi-squared test, fisher's contigency table test].	farglitazar; glyburide
827892722	rs5219	PMID:16595597	KCNJ11	Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.	yes	= 0.04	208	317	European	Efficacy	false		metformin; sulfonamides, urea derivatives
1448631796	rs1050152	PMCID:PMC5425333	SLC22A4	Allele T is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.11	4360		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
769169525	rs34241435	PMID:18004211	SCNN1B	Allele A is associated with oedema when treated with Farglitazar and Insulins And Analogues in people with Diabetes Mellitus, Type 2.	yes	= 7.0E-4	44	96	European	Toxicity	false	Please note: This polymorphism was found to have a significant association with oedema - the risk allele and minor allele was not clearly defined in this study, therefore the minor/ variant allele in Caucasian populations was used in this curation.	farglitazar; Insulins And Analogues
981240017	rs5219	PMID:22385882	KCNJ11	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c when treated with gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.036	55		European	Efficacy	false		gliclazide
1183619873	G6PD A- 202A_376G	PMID:15126005	G6PD	G6PD A- 202A_376G/A- 202A_376G is associated with Anemia, Hemolytic when treated with glibenclamide in people with Diabetes Mellitus, Type 2.	not stated		1		Unknown	Toxicity	false	The patient was homozygous for the G6PD A- haplotype which confers G6PD deficiency, therefore homozygous TT at the variant rs1050828 (nucleotide position 202, Val to Met 68) and homozygous CC at the variant rs1050829 (nucleotide position 376, Asn to Asp 126). Determined by genotyping. Alleles have been complemented to the plus chromosomal strand.	glyburide
981239763	rs316019	PMID:22882994		Allele A is not associated with efficacy to metformin as measured by HbA1c reduction when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.22	148		European	Efficacy,Metabolism/PK	false		metformin
1452538940	rs2289669	PMCID:PMC11246114	SLC47A1	Allele A is associated with increased clinical benefit to metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 0.001	124	76	Near Eastern	Efficacy	false	"""The current study found that the A allele in MATE1 rs2289669 SNP was associated with a better metformin/sulfonylurea treatment response"""	metformin; sulfonamides, urea derivatives
981239756	rs622342	PMID:22882994		Allele C is not associated with efficacy to metformin as measured by HbA1c reduction when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.95	148		European	Efficacy,Metabolism/PK	false		metformin
981481521	rs1801282	PMID:16084854	PPARG	Genotype CG is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.002	198		East Asian	Efficacy	false	The response rate to rosiglitazone treatment was lower in the Pro12Pro (CC) group vs.  Pro12Ala (CG) variant group (43.72% versus 86.67%, P =0.002). The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 -27.8mg/dL versus 24.3 -41.9 mg/dL, P=0.026). In addition, the decrease in hemoglobin A1c level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41% -1.47% versus 0.57% -1.16%, P =0 .015).	rosiglitazone
1448099041	rs10423928	PMID:27160388	GIPR	Allele A is not associated with response to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.47	140		European	Efficacy	false	The main study outcome was reduction of HbA1c after 6-months of uninterrupted treatment with glistens. The genetic association was significant with an additive genetic model.	sitagliptin; vildagliptin
655385762	rs290487	PMID:20054294	TCF7L2	Genotype TT is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	yes	= 0.043	40		East Asian	Efficacy	false		repaglinide
1451128780	rs6923761	PMID:32308134	GLP1R	Genotype AA is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.	yes	= 0.006	206		European	Efficacy	false	as measured by reduction in glycated hemoglobin over 6 months.	sitagliptin; vildagliptin
981502261	rs1470579	PMCID:PMC4002970	IGF2BP2	Genotypes AC + CC are associated with decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	yes	< 0.05	42		East Asian	Dosage,Efficacy	false	The parameters that showed decreased response were FPG(fasting plasma glucose) and PPG(postprandial plasma glucose).  The authors noted that the C allele frequency was higher in the Type 2 Diabetes patients than in the healthy controls when the entire trial population of 350 patients and 207 controls was assayed (C freq = 0.3029 vs 0.2464) .  The subset of patients treated with repaglinide all had the same CYP2C8 genotypes(with respect to *3- but exact genotypes not given) and SLCO1B1 genotypes(with respect to *1B,*5 and *15, but exact genotypes not given) .	repaglinide
1448631790	rs272893	PMCID:PMC5425333	SLC22A4	Allele T is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.57	4833		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
982035504	rs708272	PMID:12663600	CETP	Genotype GG is associated with increased response to atorvastatin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	yes	< 0.05	212		Multiple groups	Efficacy	false	Response as measured by a higher elevation in HDL cholesterol. A larger reduction in Triglycerides and CETP mass reduction was seen in patients with the GG genotype but were not significant. Genotypes were compared. The elevation in patients with the AA genotype was minimal, indicating that these patients are unlikely to benefit from atorvastatin treatment. Taq1 cut = B1 = allele G, no Taq1 site = B2 = allele A.	atorvastatin
1184407330	rs784892	PMCID:PMC4171106	AMHR2	Allele G is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	yes	= 0.008714	440		Multiple groups	Efficacy	false		metformin
1448631778	rs12943590	PMCID:PMC5425333	SLC47A2	Allele A is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no	= 0.51	4398		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
1451157700	rs757110	PMID:32468916	ABCC8; KCNJ11	Genotype CC is associated with increased likelihood of treatment failure when treated with glibenclamide or gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AC.	yes	= 0.036	262	139	Multiple groups, Malaysia: Malay, Chinese, Indian, Iban, Bidayuh, Melanau, Bajau, Kadazan, Dusun, Suluk	Efficacy	false		gliclazide; glyburide
981240002	rs5219	PMID:22385882	KCNJ11	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.036	101		European	Efficacy	false	In the log-additive model, greater mean reduction in HbA1c by 0.16% (95% CI 0.01-0.32, p=0.038) per each K-allele was observed.	sulfonamides, urea derivatives
981502270	rs4402960	PMCID:PMC4002970	IGF2BP2	Genotypes GT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	< 0.05	42		East Asian	Dosage,Efficacy	false	The parameter that showed enhanced response was PINS(postprandial serum insulin) .  The authors noted that the T allele frequency was higher in the Type 2 Diabetes patients than in the healthy controls when the entire trial population of 350 patients and 207 controls was assayed (T freq = 0.2714 vs 0.2126) .  The subset of patients treated with repaglinide all had the same CYP2C8 genotypes(with respect to *3- but exact genotypes not given) and SLCO1B1 genotypes(with respect to *1B,*5 and *15, but exact genotypes not given) .	repaglinide
1444935134	rs622342	PMID:25492374	SLC22A1	Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	yes	= 0.0009	122		Central/South Asian	Efficacy	false	Additive model. Those with the C allele were less likely to respond to treatment with metformin compared to AA homozygotes. Responders defined as those in whom there was a decrease in glycated hemoglobin (HbA1c) fall by >=0.5% and non-responders as those in whom fasting glucose >180mg% and HbA1c fall by <1% at the end of 12 weeks of treatment.	metformin
827826067	rs7903146	PMID:17519421	TCF7L2	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.015	901		Unknown	Efficacy	false		sulfonamides, urea derivatives
981758528	rs2252281	PMCID:PMC3671611	SLC47A1	Genotype CC is associated with increased response to metformin when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.	yes	= 0.01	145		Multiple groups, Caucasians and african americans	Efficacy	false	Caucasian and African-American patients homozygous for the MATE1 variant allele had a significantly larger relative change in HbA1c levels (i.e., greater response to metformin) than patients carrying at least one reference MATE1 allele.	metformin
1449295782	rs57081354	PMID:29650774	NBEA	Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.	yes	= 4e-8	1312		Multiple groups	Efficacy	false	This SNP is associated with changes in HbA1C when all races are combined.	metformin
827807890	rs13266634	PMID:20809084	SLC30A8	Allele C is associated with increased risk of Diabetes Mellitus, Type 2 as compared to allele T.	yes	< 0.05	443	229	East Asian	Other	false		
1447945867	rs2237897	PMID:26866747	KCNQ1	Allele T is not associated with response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no		443		East Asian	Efficacy	false	No difference in fasting plasma glucose (FPG) reduction and rate of treatment success.	gliclazide
1450814910	rs17584499	PMCID:PMC4011617	PTPRD	Genotype CC is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.	yes	= 0.005	67		East Asian	Efficacy	false	Patients with the CC genotype showed significantly greater decreases in postprandial plasma glucose levels after 3 months of pioglitazone treatment. However, changes in other biochemical measures were not significant.	pioglitazone
1450814898	rs1801282	PMCID:PMC4011617	PPARG	Genotype CG is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.010	67		East Asian	Efficacy	false	Patients with the CG genotype showed significantly greater decreases in fasting plasma glucose levels and triglyceride levels after 3 months of pioglitazone treatment. However, changes in other biochemical measures were not significant.	pioglitazone
1449295791	rs254271	PMID:29650774	PRPF31	Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 3.79e-6	1312		Multiple groups	Efficacy	false	This SNP is associated with changes in HbA1C when all races are combined.	metformin
1448123009	rs11212617	PMCID:PMC4916778	ATM	Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.32	140		Near Eastern	Efficacy	false	in Iranian patients. Response to metformin was defined by HbA1c and fasting blood sugar (FBS) values.	metformin
1451128748	rs163184	PMID:32308134	KCNQ1	Allele G is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.083	206		European	Efficacy	false	"as measured by reduction in glycated hemoglobin over 6 months. ""Variant rs163184 in KCNQ1 showed a tendency to association of the G allele with a smaller reduction in HbA1c levels by 0.161% per allele, although not reaching the nominal level of significance after adjustment for covariates."""	sitagliptin; vildagliptin
1451412560	rs757110	PMID:32504053	ABCC8; KCNJ11	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.43	356	1039	European	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from gnomAD, it is assumed that the A and C alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
1449564081	rs11212617	PMID:29790415	ATM	Allele C is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.04	331		European	Efficacy	false	as measured by decrease in Z score (which includes HbA1c and daily dose of insulin)   at 16 weeks, authors report as trend that was not significant after Bonferroni.	metformin
1449295802	rs2162145	PMID:29650774	CPA6	Allele T is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	yes	= 4e-6	845		European	Efficacy	false	This SNP is associated with changes in HbA1C in white patients.	metformin
1447980951	rs594709	PMCID:PMC4764723	SLC22A1	Genotypes AA + AG are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes		53		East Asian	Efficacy	false	Looked at changes in the following as measures of metformin response between AA/GA (n=50) and GG genotype (n=3): fasting blood glucose (p=0.112), postprandial blood glucose (p=0.171), fasting insulting (p=0.015), postprandial insulin (p=0.259), glycosylated hemoglobin (p=0.227), triglycerides (p=p=0.434), total cholesterol (p=0.224), low-density lipoprotein (p=0.451), high-density lipoprotein (p=0.399), homeostasis model assessment of insulin resistance (p=0.081), homeostasis model assessment of insulin sensitivity (p=0.001), homeostasis model assessment of B cell function (p=0.493), and quantitative insulin sensitivity check index (p=0.002). Also, found an interaction between this SNP and SLC47A1 rs2289669, with patients with rs594709 AA genotypes and rs2289669 AA genotypes showing higher decrease in FBG (p=0.015), PINS (p=0.041), and HOMA-IR (p-0.014) than patients with rs2289669 GA or GG genotypes. Patients with rs594709 G allele carriers and also rs2289669 AA genotype showed greater decrease in TChol (p=0.013) than GA or GG genotypes.	metformin
1452430920	rs628031	PMID:36853844	SLC22A1	Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.	yes	< 0.001	478		Unknown	Efficacy	false	Response was defined as a ≥0.5% reduction in HbA1c level at 12 week followup.	metformin
1448123019	rs628031	PMCID:PMC4916778	SLC22A1	Allele A is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	no	= 0.45	140		Near Eastern	Efficacy	false	in Iranian patients. Response to metformin was defined by HbA1c and fasting blood sugar (FBS) values.	metformin
827641483	rs5219	PMID:8897013	KCNJ11	Allele T is not associated with likelihood of Diabetes Mellitus, Type 2 as compared to allele C.	no		135	90	European	Other	false	[Full text not available]	
1452504140	rs315978	PMID:38852696	SLC22A2	Allele T is not associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.481	53	20	Near Eastern	Efficacy	false	"""Evaluation of the SLC22A2 variants rs662301 and rs315978 disclosed no statistically significant differences in genotype frequencies between responders and non-responders (p = 0.375 and p = 0.473, respectively). Similarly, no statistically significant distinctions in allele frequencies were observed between these two groups (p = 0.384 and p = 0.481, respectively)."" ""sufficient glycemic control was defined as an HbA1c concentration below 7.0 % (referred to as responders), while inadequate control (non-responders) was characterized by an HbA1c level equal to or exceeding 7.0 %"""	metformin
769218872	rs1799853	PMID:21121772	CYP2C9	Genotypes CT + TT are not associated with decreased time to stable dose of glibenclamide, gliclazide, glimepiride and tolbutamide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	no	= 0.58	207		Unknown	Dosage,Metabolism/PK	false	Please note; there was a mixed population of individuals on each sulfonylurea drug. No significant differences were found between carries of CYP2C9 allele *1/*1 vs *1/*3 or *2/*3 and *1/*2 or *2/ *2, with time to stable dose. rs1799853 refers to CYP2C9*2. [stat_test: kaplan-meier curve]	gliclazide; glimepiride; glyburide; tolbutamide
981345692	rs114202595	PMCID:PMC3477351	PAX4	Genotypes AA + AG are associated with decreased difference in postprandial plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	< 0.05	43		East Asian	Efficacy	false	Note: Alleles have been complemented to the + strand.	repaglinide
827826357	rs628031	PMID:17111267	SLC22A1	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	yes	= 0.05	9	24	East Asian	Efficacy	false	Significance given as part of stepwise analysis with age, BMI, treatment with lipid lowering agents and -43T>G (intron 1).	metformin
1452538993	rs628031	PMCID:PMC11246114	SLC22A1	Genotypes AA + AG is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.003	72	128	Near Eastern	Efficacy	false	"""Depending on metformin-induced gastrointestinal tract side effects incidence, patients are classified as tolerant or intolerant."" ""AG alleles carriers and AA alleles carriers of rs628031 variants were more susceptible to metformin side effects than GG allele carriers."""	metformin; sulfonamides, urea derivatives
769218876	rs1057910	PMID:21121772	CYP2C9	Allele C is not associated with decreased time to stable dose of glibenclamide, gliclazide, glimepiride and tolbutamide in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.58	207		Unknown	Dosage,Metabolism/PK	false	Please note; there was a mixed population of individuals on each sulfonylurea drug. No significant differences were found between carries of CYP2C9 allele *1/*1 vs *1/*3 or *2/*3 and *1/*2 or *2/ *2 with time to stable dose. rs1057910 refers to CYP2C9*3. [stat_test: kaplan-meier curve]	gliclazide; glimepiride; glyburide; tolbutamide
1448602034	rs2295490	PMCID:PMC5264271	TRIB3	Genotype AA is associated with increased response to indapamide and perindopril in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.	no	= 0.063	934	950	East Asian	Efficacy	false	SBP presented no remarkable difference between AA and AG+GG genotype groups. In the group receiving therapy, AA genotype carriers had a mean decrease of DBP of 0.8mmHg. No difference was seen in SBP.	indapamide; perindopril
1448631741	rs12208357	PMCID:PMC5425333	SLC22A1	Allele T is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.47	4557		European	Efficacy	false	This variant is not associated with metformin glycemic response assessed as HbA1c reduction in patients on metformin monotherapy.	metformin
1451581280	rs5219	PMID:34665019	KCNJ11	Allele C is not associated with increased likelihood of Hypoglycemia when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele T.	no	= 0.463	120	281	"Multiple groups, From Table 2: Race Malay Chinese Indian Iban Bidayuh Melanau Bajau Kadazan Dusun Suluk"	Toxicity	false	"""The genetic association analysis revealed that the genotypes and alleles for ABCC8 rs757110, KCNJ11 rs5219, CDKAL1 rs7756992 and KCNQ1 rs2237892 polymorphisms were all not significantly associated with sulfonylurea-induced hypoglycemia""""Sulfonylurea-induced hypoglycemia was defined as having at least one symptomatic hypoglycemia episode with or without a blood glucose level <3.9 mmol/l during the 12-month follow-up."""	sulfonamides, urea derivatives
769218879	rs1799853	PMID:21121772	CYP2C9	Allele T is not associated with increased stable dose of glibenclamide, gliclazide, glimepiride and tolbutamide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.48	152		Unknown	Dosage,Metabolism/PK	false	Please note; there was a mixed population of individuals on each sulfonylurea drug. No significant differences were found between carries of CYP2C9 allele *1/*1 vs *1/*3 or *2/*3 and *1/*2 or *2/ *2, with time to stable dose. rs1799853 refers to CYP2C9*2. [stat_test: kruskal-wallis]	gliclazide; glimepiride; glyburide; tolbutamide
1452504181	rs662301	PMID:38852696	SLC22A2	Allele T is not associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.384	55	20	Near Eastern	Efficacy	false	"""Evaluation of the SLC22A2 variants rs662301 and rs315978 disclosed no statistically significant differences in genotype frequencies between responders and non-responders (p = 0.375 and p = 0.473, respectively). Similarly, no statistically significant distinctions in allele frequencies were observed between these two groups (p = 0.384 and p = 0.481, respectively)."" ""sufficient glycemic control was defined as an HbA1c concentration below 7.0 % (referred to as responders), while inadequate control (non-responders) was characterized by an HbA1c level equal to or exceeding 7.0 %"""	metformin
1451740000	rs163184	PMID:35311356	KCNQ1	Allele G is associated with decreased clinical benefit to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele T.	yes	= 0.015	100		East Asian	Efficacy	false	"""Each G allele decreased the 48-week reduction of HbA1c by 0.34%. This result meant that patients with the homozygous mutant genotype (GG, 21%) had ∼0.68% (6.97 mmol/l) lower HbA1c reduction than those with the wild-type genotype (TT, 28%). """	exenatide
1452538740	rs5219	PMCID:PMC11246114	ABCC8; KCNJ11	Genotypes CT + TT is associated with increased clinical benefit to metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	= 0.006	124	76	Near Eastern	Efficacy	false	"""Relative to the rs5219 EE genotype carriers, the EK and KK genotype carriers responded better to combination therapy."" However Table 4 shows E as higher frequency in responders than non-responders.  Mapped E to C and K to T."	metformin; sulfonamides, urea derivatives
699639130	rs10192566	PMID:18693052	LPIN1	Allele G is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele C.	yes	= 0.005	262		East Asian	Efficacy	false	Patients with the G allele in rs10192566 had a larger decrease in fasting plasma glucose, 2-h postprandial glucose, and HbA1c than those without.	rosiglitazone
827807933	rs13266634	PMID:20809084	SLC30A8	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	< 0.05	48		East Asian	Efficacy	false		repaglinide
1185235790	rs5219	PMID:25115353	KCNJ11	Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	yes	= 0.042	108		East Asian	Efficacy	false	"Patients with the TT genotype (referred to by its amino acids, ""KK"" in the paper) were significantly more likely to attain the standard fasting glucose level as compared to patients with the CC or CT genotypes. Significant after adjustment for age, gender and body mass index (BMI) at baseline. Patients received gliclazide for 16 weeks."	gliclazide
981345683	rs1801262	PMCID:PMC3477351	NEUROD1	Genotypes CT + TT are associated with decreased difference in postprandial plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	yes	< 0.01	43		East Asian	Efficacy	false	Note: Alleles have been complemented to the + strand.	repaglinide
699639389	rs12255372	PMID:17519421	TCF7L2	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	yes	= 0.005	901		Unknown	Efficacy	false		sulfonamides, urea derivatives
1447980961	rs2289669	PMCID:PMC4764723	SLC47A1	Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.	yes		53		East Asian	Efficacy	false	Looked at changes in the following as measures of metformin response between AA/GA (n=50) and GG genotype (n=3): fasting blood glucose (p=0.112), postprandial blood glucose (p=0.171), fasting insulting (p=0.015), postprandial insulin (p=0.259), glycosylated hemoglobin (p=0.227), triglycerides (p=p=0.434), total cholesterol (p=0.224), low-density lipoprotein (p=0.451), high-density lipoprotein (p=0.399), homeostasis model assessment of insulin resistance (p=0.081), homeostasis model assessment of insulin sensitivity (p=0.001), homeostasis model assessment of B cell function (p=0.493), and quantitative insulin sensitivity check index (p=0.002). Also, found an interaction between this SNP and SLC47A1 rs2289669, with patients with rs594709 AA genotypes and rs2289669 AA genotypes showing higher decrease in FBG (p=0.015), PINS (p=0.041), and HOMA-IR (p-0.014) than patients with rs2289669 GA or GG genotypes. Patients with rs594709 G allele carriers and also rs2289669 AA genotype showed greater decrease in TChol (p=0.013) than GA or GG genotypes.	metformin
1451412589	rs7903146	PMID:32504053	TCF7L2	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.65	356	1039	European	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from gnomAD, it is assumed that the C and T alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide
1451905400	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:34656068	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) are associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	= 0.039	2341		East Asian	Efficacy	false	CYP2C19 poor metabolizers had lower risk of SU treatment failure and were more likely to reach the HbA1c treatment target < 7% than wild-type carriers (CYP2C19 *1/*1).	sulfonamides, urea derivatives
827806117	rs391300	PMID:21933224	SRR	Genotypes CC + CT are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.	yes	= 0.024	44		East Asian	Efficacy	false		metformin
982044541	rs5186	PMID:19286758	AGTR1	Genotypes AC + CC are associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	yes	= 0.022	59		Unknown	Efficacy	false	99mTc-MAG3 clearance (MAG3cle) values were higher in patients who were carriers for the C allele, as compared to AA homozygotes, after treatment with captopril. MAG3cle provides an estimation of effective renal plasma flow (ERPF), and therefore of responsiveness to captopril treatment.	captopril
827777953	rs72552763	PMID:21989078	SLC22A1	Genotype GAT/del is associated with decreased trough metformin steady-state concentration when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.	yes	= 0.027	371		Unknown	Metabolism/PK,Other	false	The statistical significance using mixed-effect modeling was obtained between the patient homozygous for the wild-type and the patient heterozygous for the alleles (P=0.027). In the adjusted Wald test for rs72552763 in which all groups (wild-type, heterozygous, and homozygous (n=1)) were compared, the significance was the P value equal to 0.06.	metformin
1452538980	rs72552763	PMCID:PMC11246114	SLC22A1	Genotype GAT/del is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.	yes	= 0.023	72	128	Near Eastern	Efficacy	false	"""Depending on metformin-induced gastrointestinal tract side effects incidence, patients are classified as tolerant or intolerant."" ""GAT/del allele carriers were more susceptible to metformin adverse effects than GAT/GAT allele carriers of rs72552763 variants."" del/del was not significantly different but allelic comparison was significant."	metformin; sulfonamides, urea derivatives
982044530	rs1799752	PMID:19286758	ACE	Genotype del/del is associated with decreased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	yes	= 0.005	59		Unknown	Efficacy	false	99mTc-MAG3 clearance (MAG3cle) values increased with each addition of an ATA... allele, after treatment with captopril. MAG3cle provides an estimation of effective renal plasma flow (ERPF), and therefore of responsiveness to captopril treatment.	captopril
1043858627	rs1799752	PMID:11699055	ACE	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased likelihood of ACEI-related cough due to perindopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	yes	= 0.006	189		East Asian	Toxicity	false	This study examined both male and female patients with Type 2 Diabetes Mellitus. When stratified by gender, this association was only seen in female patients; no genetic association with ACEI-related cough was seen in male patients.	perindopril
1451412861	rs7756992	PMID:32504053	CDKAL1	Allele G is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.37	78	227	African American/Afro-Caribbean	Toxicity	false	The paper does not specify which alleles were found in the study cohort. Based on reported allele frequencies from ALFA, it is assumed that the A and G alleles were identified. Bonferroni-adjusted threshold for statistical significance was set at p<0.0033.	glimepiride; glipizide; glyburide